Navigation Links
New Vaccine to Bring Dramatic Decrease in Cervical Cancer Deaths

GlaxoSmithKline has reported that its experimental vaccine against a virus that causes cervical cancer could bring about a decrease in the number// of cases and deaths from the illness by up to 76 percent.

Their vaccine, Cervarix prevents the infection from two strains of the human papillomavirus (HPV) which is responsible for about 70 percent of cases of cervical cancer.

At a medical conference in Prague researchers who undertook a computer model study funded by GlaxoSmithKline predicted the impact the vaccine would have in Britain if all 12 year-old girls were vaccinated.

According to them if coverage was 100 percent, the company claimed that it could lead to a decrease in deaths by 76 percent. The research revealed that eighty percent vaccine coverage could reduce cases and deaths by 61 percent.

The researchers said, "Over the lifetime of a UK cohort of 12 year old females, the model predicts the occurrence of 2,636 cervical cancer cases and 1,403 cancer deaths without vaccination. With vaccination at 100 percent coverage, the forecast would be as low as 632 cancer cases (76 percent reduction) and 335 cancer deaths (also 76 percent reduction)."

These estimates have been made based on the vaccination being paired with the existing cervical screening program. Dr Anne Szarewski, of the charity Cancer Research UK, said HPV vaccination offers hope of reducing cases and preventing deaths from the illness.

She said, "Currently there are 3,000 women in the UK who get cervical cancer each year -- despite a highly efficient screening program."

Competing drug manufacturer Merck & Co Inc has also produced a vaccine to prevent cervical cancer. Their vaccine, Gardasil has been recommended by the European Medicines Agency to prevent cancer caused by four strains of HPV. The U.S. Food and Drug Administration in June has approved it.


NLA
'"/>




Page: 1

Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Vaccine for Alzheimer’s diseas
4. Health Officials Recommend Flu Vaccine
5. Smallpox Vaccine May Help Fight Cervical Cancer
6. Panacea Biotech To Market Anthrax Vaccine
7. New Prostate Cancer Vaccine Shows Promise
8. Drug Firm Offers to Donate Smallpox Vaccine
9. Vaccine guards against shingles
10. Vaccine for septic conditions
11. A new Vaccine for Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... ... Patel M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is ... Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), ... labor and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding ... the hospital and decide to donate. , “Women’s Hospital at Renaissance has been ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
(Date:4/28/2017)... ... 2017 , ... Bill Howe started his sewer and drain company in 1980 ... joined the team, the Bill Howe brand was born and they began cultivating their ... back to the San Diego community in which they worked, lived and were raising ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: